Mucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• Polysaccharide (PS)-encapsulated bacteria like Hib, pneumococcus, meningococcus, and GBS cause significant early childhood diseases.
• Native PS vaccines are less effective in infants due to their T-cell independent nature, failing to induce immunological memory.
• PS-protein conjugate vaccines enhance immunogenicity in young children but show limited efficacy against mucosal infections like otitis media.

Purpose of the Study:

• To evaluate the efficacy of mucosal immunization with PS-protein conjugate vaccines against encapsulated bacteria.
• To assess the induction of systemic and mucosal immune responses following mucosal vaccination.
• To explore the potential of mucosal immunization to overcome neonatal and infant susceptibility to encapsulated bacterial infections.

Main Methods:

• Experimental animals were immunized mucosally with conjugate vaccines against Hib, pneumococcus, meningococcus, and GBS.
• Neonatal mice received pneumococcal conjugate vaccine with LT-K63 adjuvant via mucosal versus parenteral routes.
• Immune responses, including antibody production and immunological memory, were analyzed.

Main Results:

• Mucosal immunization induced protective systemic and mucosal immune responses against various encapsulated bacteria.
• Protection was observed against bacterial carriage, otitis media, and invasive diseases in challenge models.
• Mucosal immunization in neonatal mice with pneumococcal conjugate and adjuvant was superior to parenteral immunization in generating protective antibodies and PS-specific memory.

Conclusions:

• Mucosal immunization with PS-protein conjugate vaccines provides a promising strategy for protecting against encapsulated bacterial infections.
• This approach elicits robust systemic and mucosal immunity, offering protection against both invasive and mucosal diseases.
• Mucosal vaccination, particularly in early life, circumvents limitations of traditional parenteral routes and enhances protection in vulnerable infants.